Welcome to our dedicated page for Relief Hldg news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on Relief Hldg stock.
MindMaze Therapeutics Holding SA develops and commercializes precision digital treatments for neurological diseases and brain disorders. Its brain technology platform integrates software, proprietary sensors, telehealth, and AI-driven data analytics to support care from acute hospital treatment to outpatient and home-based therapy.
Company news covers FDA-cleared and CE-marked neurotherapeutics for areas such as stroke and Parkinson's disease, reimbursement strategy across healthcare systems, clinical validation, and R&D expansion into adjacent neurological indications. Updates also include the completed business combination that formed the MindMaze Therapeutics identity, along with shareholder voting, governance, capital-structure, and financial-reporting matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Relief Therapeutics announced positive 12-month stability data for RLF-100 ®, an investigational formulation of aviptadil acetate for inhaled and intravenous administration. Both formulations demonstrated high purity levels after one year across various temperature conditions, confirming previous findings at three and six months. In response to these results, Relief plans to amend its provisional patent application, potentially extending exclusivity until 2042, factoring in possible Hatch-Waxman extensions.
CEO Jack Weinstein emphasized the commercial potential of the stable formulation, aiming to establish RLF-100 ® as a standard treatment for respiratory failure. The FDA previously granted Orphan Drug designation for RLF-100 ® targeting pulmonary sarcoidosis.